Mazdutide

Mazdutide (LY3305677) — Dual GLP-1/Glucagon Receptor Agonist for Metabolic Research

Mazdutide (INN; also known as LY3305677) is a novel long-acting dual agonist peptide targeting both glucagon-like peptide-1 (GLP-1) and glucagon receptors. Developed by Innovent Biologics in collaboration with Eli Lilly, mazdutide has been the subject of multiple clinical trials published in The Lancet Diabetes & Endocrinology and Nature Medicine (2023-2024), demonstrating significant effects on body weight reduction and glycemic control. As a dual-action incretin analog, mazdutide provides researchers with a unique pharmacological tool for studying the synergistic metabolic effects of simultaneous GLP-1 and glucagon receptor engagement.

Mechanism of Action

Mazdutide is engineered as a peptide-Fc fusion construct with balanced agonist activity at both GLP-1R and GCGR. The GLP-1 receptor component activates Gs-coupled cAMP signaling in pancreatic beta cells, enhancing glucose-dependent insulin secretion, slowing gastric emptying, and activating hypothalamic satiety centers. Simultaneously, the glucagon receptor agonist component stimulates hepatic glycogenolysis, increases energy expenditure through thermogenesis in brown adipose tissue, and promotes hepatic lipid oxidation. The dual mechanism produces complementary metabolic effects—GLP-1R mediating appetite suppression and insulin secretion, while GCGR drives energy expenditure and fat oxidation.

Key Research Areas

• Weight Management: Phase II/III clinical trials have demonstrated that Mazdutide produces dose-dependent body weight reductions of 10-15% over 24-48 week treatment periods in obese subjects, with superior weight loss kinetics compared to GLP-1-only receptor agonists in head-to-head preclinical comparisons.
• Glycemic Control: Research has documented significant HbA1c reductions (1.5-2.0 percentage points) in type 2 diabetes models, with the dual agonism providing both insulin-dependent (GLP-1R) and insulin-independent (GCGR-mediated hepatic glucose output suppression) glycemic control mechanisms.
• Energy Expenditure: Indirect calorimetry studies have demonstrated increased resting metabolic rate and enhanced diet-induced thermogenesis following mazdutide administration, attributed to GCGR-mediated activation of brown adipose tissue UCP1 expression and hepatic FGF21 secretion.
• Hepatic Lipid Metabolism: Research has observed significant reductions in intrahepatic triglyceride content (measured by MRI-PDFF), decreased serum ALT levels, and improved NAFLD activity scores in preclinical NASH models treated with dual GLP-1/glucagon agonists.

Technical Specifications

• Dosage per vial: 5mg lyophilized powder
• Purity: ≥98% (HPLC verified)
• Storage: -20°C, protected from light

Why Researchers Choose Peptides BioLab

Every batch of Mazdutide supplied by Peptides BioLab undergoes rigorous HPLC and mass spectrometry analysis, ensuring ≥98% purity verified by an independent Certificate of Analysis (CoA). Our product is supplied as a lyophilized powder for maximum stability, shipped worldwide in temperature-controlled packaging.

Related Research Peptides

Researchers studying incretin biology and metabolic regulation may also find these compounds relevant: AOD-9604, 5-Amino-1MQ, and MOTS-c. For a complete overview, browse our Weight Loss Research collection.

For research purposes only — Not for human consumption. All products are intended solely for in-vitro research and laboratory use.